Citing two unnamed sources, the Financial Times reported that the company has hired advisors from Centerview Partners to assess a potential sale. According to the article, Embecta's "lackluster" stock performance, low market value, and similarity to other companies that have recently attracted buyout interest could make it a good acquisition candidate. The media outlet said Embecta did not respond to a request for comment and Centerview Partners declined to comment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,